Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. announced on July 22, 2025, that abstracts for zipalertinib's REZILIENT1 and REZILIENT2 trials have been accepted for presentation. These data will be featured as mini oral presentations at the International Association for the Study of Lung Cancer's (IASLC) 2025 World Conference on Lung Cancer (WCLC), scheduled for September 6-9, 2025, in Barcelona, Spain.
The acceptance of these abstracts for presentation at a prominent international oncology conference underscores the continued scientific interest and potential clinical relevance of zipalertinib. This provides an important platform to share further insights into the drug's efficacy and safety profile in non-small cell lung cancer (NSCLC) patients.
The presentations will cover data from both the pivotal REZILIENT1 trial and the REZILIENT2 trial, which are evaluating zipalertinib in different cohorts of NSCLC patients with EGFR exon 20 insertion mutations. This ongoing dissemination of clinical data is crucial for informing the medical community and supporting the drug's development pathway.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.